Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189690 | 1.00 | NAMPT (0.42) | NAMPTDGAT1SYKROCK2TMPRSS2 | |
| SCHEMBL1188339 | 0.92 | DGAT1 (0.50) | NAMPTDGAT1SYKTMPRSS2 | |
| SCHEMBL1188342 | 0.92 | DGAT1 (0.50) | NAMPTDGAT1SYKTMPRSS2 | |
| SCHEMBL1187751 | 0.91 | NAMPT (0.41) | NAMPTSYKROCK2TMPRSS2 | |
| SCHEMBL1187749 | 0.91 | NAMPT (0.41) | NAMPTSYKROCK2TMPRSS2 | |
| SCHEMBL1188469 | 0.90 | KCNA1 (0.48) | NAMPTDGAT1SYKTMPRSS2 | |
| SCHEMBL1188466 | 0.90 | KCNA1 (0.48) | NAMPTDGAT1SYKTMPRSS2 | |
| SCHEMBL1187348 | 0.90 | NPC1 (0.48) | NAMPTDGAT1SYKROCK2PKM | |
| SCHEMBL1187351 | 0.90 | NPC1 (0.48) | NAMPTDGAT1SYKROCK2PKM | |
| SCHEMBL1188786 | 0.90 | NAMPT (0.47) | NAMPTDGAT1TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735425-B2 | Tetrahydroisoquinoline derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2256105-B1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2256105-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DGAT1, DGAT2, DLAT | NAMPT 934/4885DGAT1 1/4885SYK 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.